The current hullabaloo about new recommendations to delay the use of mammograms and Pap smears is just part of a huge debate afoot in the medical establishment about the value of cancer screening tests in general-mammography, PSA, Pap Test, CT Scan, etc. There is widening concern that too often false-positives result or non-threatening tumors may be discovered, leading to more costly, invasive testing, unnecessary toxic treatment and undue stress. What is a responsible medical consumer supposed to do?
F.A.C.T. ’s position has always been that these tests are too invasive, too often inaccurate, too expensive and far too limited in scope to be of any real value. Because we view cancer as a systemic disease — not just the tumor or cancer cells — we believe it is more logical to focus on detecting — and correcting — any imbalance in the body chemistry that could be the cause of abnormal cell production. This is why we have long recommended the Human Chorionic Gonatrophin (HCG) Urine Immunoassay — developed in 1957 by Manual Navarro, M.D. and used successfully by many cancer patients on a biorepair program for early detection and to monitor their progress.
To learn more about the scientific basis and purpose of this test, including easy instructions for individuals to prepare a sample for quantitative analysis, read this:
HCG Test — A Non-Invasive Diagnostic for Cancer (downloadable pdf)